Iloperidone (Fanapt) vs Quetiapine (Seroquel XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Iloperidone (Fanapt)
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Reported efficacy
Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)
Result source: NCT00254202
Quetiapine (Seroquel XR)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00640601 · Phase 3 · completed
This was a nonrandomized, single-group, open-label study of 295 treated participants, without a placebo or active comparator. Although 56.88% were reported to have improved clinical benefit on the primary CGI-CB measure, the uncontrolled design cannot determine how much of the improvement was due to quetiapine rather than other factors.
Next expected readout: February 2032 · NCT07152184 (registry estimate)
Reported efficacy
Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8) (not_applicable)
Result source: NCT00640601
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Iloperidone (Fanapt) | Quetiapine (Seroquel XR) |
|---|---|---|
| PANSS total, change | -12 vs -7.1−4.9 vs placeboNCT002542021 other result
| -24 vs -15.9−8.1 vs placeboNCT018103801 other result
|
| CGI-S, change | —Trial running · NCT06961968 | -1.4 vs -0.9−0.5 vs placeboNCT018103801 other result
|
| PANSS response | —Trial running · NCT06961968 | 62.7% vs 32.1%+30.6 vs placeboNCT01810380 |
| PSP, change | —Trial running · NCT06961968 | 15.3 vs 9.4+5.9 vs placeboNCT01810380 |
| Relapse (% of patients) | —Trial running · NCT06961968 | —Not posted · NCT00159770 |
PANSS total, change
- Iloperidone (Fanapt)
- -12 vs -7.1−4.9 vs placeboNCT00254202
1 other result
- 1.1 vs 12.4 NCT01291511
- Quetiapine (Seroquel XR)
- -24 vs -15.9−8.1 vs placeboNCT01810380
1 other result
- 102.3 vs 100.5 NCT00640562
CGI-S, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Quetiapine (Seroquel XR)
- -1.4 vs -0.9−0.5 vs placeboNCT01810380
1 other result
- -1.5 vs -1.0 NCT00640562
PANSS response
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Quetiapine (Seroquel XR)
- 62.7% vs 32.1%+30.6 vs placeboNCT01810380
PSP, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Quetiapine (Seroquel XR)
- 15.3 vs 9.4+5.9 vs placeboNCT01810380
Relapse (% of patients)
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Quetiapine (Seroquel XR)
- —Not posted · NCT00159770
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Iloperidone (Fanapt): 4 of 4 rows · Quetiapine (Seroquel XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Iloperidone (Fanapt) | Quetiapine (Seroquel XR) |
|---|---|---|
| Dropout rate | 34.6%a NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results51.3%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 30.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 31.5%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence 18.8%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 12.5%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 13.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 38%b NCT00640601 · Phase 3 show 7 more results16.5% NCT00640562 · Phase 3 —Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence —Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 20% NCT00954122 · Phase 4 · registry result, not featured evidence 30.2% NCT00779506 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 20.8%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results14.5%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 10.4%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 15%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 14.6%b NCT00640601 · Phase 3 show 7 more results7.3% NCT00640562 · Phase 3 —Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence —Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 2.9% NCT00954122 · Phase 4 · registry result, not featured evidence 4.2% NCT00779506 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 2.6%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0.7%a NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results—Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 4%Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 2.7%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 14.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 7.1%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 11.2%b NCT00640601 · Phase 3 show 7 more results3.7% NCT00640562 · Phase 3 0%Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence 0%Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 2.9% NCT00954122 · Phase 4 · registry result, not featured evidence 0% NCT00779506 · Phase 4 · registry result, not featured evidence 1.3%Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence —Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a headache 20.3% (placebo 19.7%) dizziness 17% (placebo 7.5%) sedation 12.7% (placebo 8.2%) NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 18 more resultsdizziness 11.6% (placebo 2.7%) somnolence 8.3% (placebo 0%) dry mouth 6.8% (placebo 0%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dizziness 2.6% (placebo 2.7%) headache 2% (placebo 3.3%) insomnia 2% (placebo 4.7%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dry mouth 17.9% dizziness 17.5% somnolence 14.2% NCT01207414 · Phase 4 · registry result, not featured evidence dizziness 22.3% dry mouth 20.8% insomnia 9.6% NCT01207414 · Phase 4 · registry result, not featured evidence 625 mg injection site pain 66.7% injection site induration 60% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 625 mg headache 20% nasal congestion 20% anxiety 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg injection site pain 60% injection site induration 26.7% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg nasal congestion 33.3% constipation 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg back pain 7.1% constipation 7.1% headache 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg insomnia 20% headache 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg constipation 14.3% headache 14.3% anxiety 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg headache 33.3% insomnia 33.3% dyspepsia 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg injection site pain 53.3% headache 26.7% nasal congestion 26.7% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg nasal congestion 40% headache 26.7% oropharyngeal pain 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg pruritus 50% throat irritation 50% upper respiratory tract infection 50% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg constipation 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg blood creatine phosphokinase increased 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg dizziness 50% headache 50% agitation 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence | show 5 more resultssomnolence 3.2% delusion 1.6% dizziness 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence psychotic disorder 1.6% sedation 1.6% sleep disorder 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence constipation 25.5% insomnia 23.4% sedation 12.8% NCT00779506 · Phase 4 · registry result, not featured evidence somnolence 22.2% (placebo 5%) weight increased 13.1% (placebo 3.7%) dizziness 11.8% (placebo 0.6%) NCT01810380 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 21 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Iloperidone (Fanapt)
show 1 more result
show 3 more results
Quetiapine (Seroquel XR)
show 2 more results
show 1 more result
show 1 more result
show 2 more results
show 1 more result
show 1 more result
+ 21 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Quetiapine (Seroquel XR)'s landscape